JP2020502155A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020502155A5 JP2020502155A5 JP2019532072A JP2019532072A JP2020502155A5 JP 2020502155 A5 JP2020502155 A5 JP 2020502155A5 JP 2019532072 A JP2019532072 A JP 2019532072A JP 2019532072 A JP2019532072 A JP 2019532072A JP 2020502155 A5 JP2020502155 A5 JP 2020502155A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- drugs
- composition according
- plasminogen
- myocardial damage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 230000003680 myocardial damage Effects 0.000 claims 11
- 102000013566 Plasminogen Human genes 0.000 claims 10
- 108010051456 Plasminogen Proteins 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 9
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- 201000001320 Atherosclerosis Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 206010061218 Inflammation Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 208000028867 ischemia Diseases 0.000 claims 3
- 206010002383 Angina Pectoris Diseases 0.000 claims 2
- 206010003178 Arterial thrombosis Diseases 0.000 claims 2
- 208000003241 Fat Embolism Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 206010047249 Venous thrombosis Diseases 0.000 claims 2
- 206010002906 aortic stenosis Diseases 0.000 claims 2
- 201000002064 aortic valve insufficiency Diseases 0.000 claims 2
- 230000006793 arrhythmia Effects 0.000 claims 2
- 206010003119 arrhythmia Diseases 0.000 claims 2
- 210000004413 cardiac myocyte Anatomy 0.000 claims 2
- 230000015271 coagulation Effects 0.000 claims 2
- 238000005345 coagulation Methods 0.000 claims 2
- 208000029078 coronary artery disease Diseases 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 208000006887 mitral valve stenosis Diseases 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 208000031225 myocardial ischemia Diseases 0.000 claims 2
- 210000004165 myocardium Anatomy 0.000 claims 2
- 230000010410 reperfusion Effects 0.000 claims 2
- 230000035939 shock Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000003017 Aortic Valve Stenosis Diseases 0.000 claims 1
- 206010002915 Aortic valve incompetence Diseases 0.000 claims 1
- 208000037157 Azotemia Diseases 0.000 claims 1
- 201000000057 Coronary Stenosis Diseases 0.000 claims 1
- 206010011089 Coronary artery stenosis Diseases 0.000 claims 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 claims 1
- 208000005189 Embolism Diseases 0.000 claims 1
- 208000004930 Fatty Liver Diseases 0.000 claims 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 claims 1
- 206010019708 Hepatic steatosis Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000020128 Mitral stenosis Diseases 0.000 claims 1
- 206010027727 Mitral valve incompetence Diseases 0.000 claims 1
- 208000009525 Myocarditis Diseases 0.000 claims 1
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000031481 Pathologic Constriction Diseases 0.000 claims 1
- 102000001938 Plasminogen Activators Human genes 0.000 claims 1
- 108010001014 Plasminogen Activators Proteins 0.000 claims 1
- 206010037601 Pyelonephritis chronic Diseases 0.000 claims 1
- 206010062237 Renal impairment Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 230000002924 anti-infective effect Effects 0.000 claims 1
- 239000003416 antiarrhythmic agent Substances 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 229940127219 anticoagulant drug Drugs 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 229940127088 antihypertensive drug Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 239000003101 antineoplastic hormone agonist and antagonist Substances 0.000 claims 1
- 229940127218 antiplatelet drug Drugs 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 208000026099 carbohydrate metabolic disease Diseases 0.000 claims 1
- 239000000496 cardiotonic agent Substances 0.000 claims 1
- 230000003177 cardiotonic effect Effects 0.000 claims 1
- 201000006368 chronic pyelonephritis Diseases 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 210000004351 coronary vessel Anatomy 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 229940030606 diuretics Drugs 0.000 claims 1
- 208000010706 fatty liver disease Diseases 0.000 claims 1
- 239000003527 fibrinolytic agent Substances 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 230000005977 kidney dysfunction Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000004089 microcirculation Effects 0.000 claims 1
- 208000005907 mitral valve insufficiency Diseases 0.000 claims 1
- 230000010016 myocardial function Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 208000008494 pericarditis Diseases 0.000 claims 1
- 229940127126 plasminogen activator Drugs 0.000 claims 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims 1
- 239000011251 protective drug Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 208000004124 rheumatic heart disease Diseases 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
- 230000036262 stenosis Effects 0.000 claims 1
- 208000037804 stenosis Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 229940034208 thyroxine Drugs 0.000 claims 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 208000009852 uremia Diseases 0.000 claims 1
- 229940124549 vasodilator Drugs 0.000 claims 1
- 239000003071 vasodilator agent Substances 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2016110174 | 2016-12-15 | ||
| CNPCT/CN2016/110174 | 2016-12-15 | ||
| CN2016110172 | 2016-12-15 | ||
| CNPCT/CN2016/110172 | 2016-12-15 | ||
| CN2016110168 | 2016-12-15 | ||
| CNPCT/CN2016/110168 | 2016-12-15 | ||
| PCT/CN2017/089068 WO2018107707A1 (zh) | 2016-12-15 | 2017-06-19 | 一种改善心脏病变的方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020502155A JP2020502155A (ja) | 2020-01-23 |
| JP2020502155A5 true JP2020502155A5 (https=) | 2020-08-06 |
| JP7194440B2 JP7194440B2 (ja) | 2022-12-22 |
Family
ID=62558191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019532072A Active JP7194440B2 (ja) | 2016-12-15 | 2017-06-19 | 心臓病変を改善するための方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11389515B2 (https=) |
| EP (1) | EP3556385A4 (https=) |
| JP (1) | JP7194440B2 (https=) |
| CN (1) | CN110114081A (https=) |
| CA (1) | CA3047175A1 (https=) |
| TW (1) | TWI677348B (https=) |
| WO (1) | WO2018107707A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018107686A1 (zh) | 2016-12-15 | 2018-06-21 | 深圳瑞健生命科学研究院有限公司 | 一种治疗动脉粥样硬化及其并发症的方法 |
| JP7213552B2 (ja) | 2016-12-15 | 2023-01-27 | タレンゲン インターナショナル リミテッド | 肝の繊維化を予防及び治療するための方法 |
| JP7168990B2 (ja) | 2016-12-15 | 2022-11-10 | タレンゲン インターナショナル リミテッド | 肥満症を予防および治療するための方法および薬物 |
| TWI677348B (zh) | 2016-12-15 | 2019-11-21 | 大陸商深圳瑞健生命科學研究院有限公司 | 一種改善心臟病變的方法 |
| CA3067890A1 (en) * | 2017-06-19 | 2018-12-27 | Talengen International Limited | Method for regulating and controling glp-1/glp-1r and drug |
| EP4140498A4 (en) | 2020-05-11 | 2023-11-01 | Talengen International Limited | Method and drug for treating spinal muscular atrophy |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4245051A (en) | 1978-03-30 | 1981-01-13 | Rockefeller University | Human serum plasminogen activator |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| JPS62153224A (ja) | 1985-12-27 | 1987-07-08 | Green Cross Corp:The | プラスミノゲン製剤 |
| GB8721951D0 (en) * | 1987-09-18 | 1987-10-28 | Thrombosis Research Trust | Organic compounds |
| JP2764264B2 (ja) | 1987-10-01 | 1998-06-11 | 株式会社ミドリ十字 | 線溶活性増強剤 |
| AT402367B (de) | 1990-10-11 | 1997-04-25 | Immuno Ag | Pharmazeutische zubereitung auf basis von lys-plasminogen |
| WO1994001128A1 (en) | 1992-07-01 | 1994-01-20 | Beth Israel Hospital Boston | Enhancement of thrombolytic therapy with deglycosylated plasminogen |
| US5520912A (en) * | 1993-07-02 | 1996-05-28 | Immuno Aktiengesellschaft | Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen |
| DK125693D0 (https=) | 1993-11-05 | 1993-11-05 | Novo Nordisk As | |
| DE4411143C2 (de) | 1994-03-30 | 1996-08-01 | Immuno Ag | Thrombosemittel |
| ES2434840T3 (es) | 1995-07-27 | 2013-12-17 | Genentech, Inc. | Formulación de proteína liofilizada isotónica estable |
| JP2002510209A (ja) | 1997-06-26 | 2002-04-02 | カロリンスカ イノベイションズ アクチボラゲット | インビボで血管形成を調節することができるプラスミノーゲンのクリングルドメイン１−５ |
| US7317003B2 (en) | 1998-09-04 | 2008-01-08 | National University Of Singapore | Small peptides having anti-angiogenic and endothelial cell inhibition activity |
| AU3605800A (en) | 1999-02-24 | 2000-09-14 | Henry Ford Health System | An anti-angiogenic kringle protein and its mutants |
| US6899877B2 (en) | 1999-03-09 | 2005-05-31 | Minu, L.L.C. | Process for generating plasmin in the vitreous of the eye and inducing separation of the posterior hyaloid from the retina |
| US6964764B2 (en) | 1999-11-13 | 2005-11-15 | Talecris Biotherapeutics, Inc. | Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin |
| US7544500B2 (en) | 1999-11-13 | 2009-06-09 | Talecris Biotherapeutics, Inc. | Process for the production of a reversibly inactive acidified plasmin composition |
| US20020159992A1 (en) | 2000-09-29 | 2002-10-31 | Jack Henkin | Antiangiogenic polypeptides and methods for inhibiting angiogenesis |
| AU2002239414A1 (en) | 2000-11-02 | 2002-05-27 | Bristol-Myers Squibb Company | Modified plasminogen related peptide fragments and their use as angiogenesis inhibitors |
| WO2003014145A2 (en) | 2001-08-10 | 2003-02-20 | Novartis Ag | Peptides that bind to atherosclerotic lesions |
| US7067492B2 (en) * | 2001-09-06 | 2006-06-27 | Omnio Ab | Method of promoting healing of a tympanic membrane perforation |
| US7202066B2 (en) | 2002-01-29 | 2007-04-10 | Carrington Laboratories, Inc. | Combination of a growth factor and a protease enzyme |
| MXPA04007585A (es) * | 2002-02-06 | 2005-09-20 | N Zyme Biotec Gmbh | Metodo para la produccion de proteinas recombinantes en microorganismos. |
| US20050124036A1 (en) * | 2002-02-06 | 2005-06-09 | Rudy Susilo | Method for producing recombinant proteins in micro-organisms |
| US20030199464A1 (en) | 2002-04-23 | 2003-10-23 | Silviu Itescu | Regeneration of endogenous myocardial tissue by induction of neovascularization |
| BR0310100A (pt) | 2002-05-17 | 2007-04-27 | Esperion Therapeutics Inc | métodos para tratar, prevenir ou reduzir a lesão de reperfusão isquêmica em um tecido ou órgão, e para prevenir ou tratar de uma condição associada com a privação de oxigênio, seguida por suprimento de oxigênio aumentado a um tecido ou órgão em necessidade disto |
| CN1451746A (zh) | 2003-03-20 | 2003-10-29 | 广州市启源生物科技有限公司 | 人纤溶酶原Kringle 5缺失突变重组多肽 |
| ATE362001T1 (de) | 2003-09-24 | 2007-06-15 | Alstom Technology Ltd | Legierung zum löten und deren verwendung |
| US8357147B2 (en) | 2005-08-17 | 2013-01-22 | Spinal Restoration, Inc. | Method for repairing intervertebral discs |
| FR2882654B1 (fr) * | 2005-03-01 | 2007-04-27 | Servier Lab | Utilisation de derives de la diosmetine pour le traitement et la prevention des pathologies thrombotiques |
| CN101189339A (zh) * | 2005-03-22 | 2008-05-28 | 美得思达健康有限公司 | 诊断和治疗心血管疾病的递送系统和方法 |
| US20060257391A1 (en) | 2005-05-11 | 2006-11-16 | Bausch & Lomb Incorporated | Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions |
| ES2453496T3 (es) * | 2006-08-28 | 2014-04-08 | Omnio Healer Ab | Diana farmacológica novedosa de prevención y tratamiento de enfermedad periodontal, mejora de la cicatrización de heridas periodontales y promoción de la salud oral |
| US8318661B2 (en) | 2006-08-28 | 2012-11-27 | Omnio Healer Ab | Candidates against infection |
| CN101219219B (zh) | 2007-01-10 | 2013-02-13 | 北京普罗吉生物科技发展有限公司 | 包含血管抑素或其片段的复合物、其制备方法及应用 |
| CN101015686B (zh) | 2007-02-06 | 2010-05-19 | 中国人民解放军军事医学科学院基础医学研究所 | 一种溶栓药物增效剂及其制备方法 |
| US20080200387A1 (en) | 2007-02-15 | 2008-08-21 | Hua-Lin Wu | Anti-angiogenic protein, composition and use thereof |
| AR067446A1 (es) | 2007-07-11 | 2009-10-14 | Otsuka Pharma Co Ltd | Un medicamento para tratar higado graso que comprende cilostazol |
| JP5539896B2 (ja) | 2007-11-29 | 2014-07-02 | グリフオルス・セラピユーテイクス・インコーポレーテツド | 組換え的に改変されたプラスミン |
| BRPI0906867A2 (pt) | 2008-01-09 | 2019-09-24 | Intrexon Corp | inibidores terapêuticos da função pai-1 e métodos de uso dos mesmo |
| US20090208448A1 (en) | 2008-02-15 | 2009-08-20 | Solomon Keith R | Inhibition of angiogenesis |
| EP2415755A4 (en) | 2009-03-31 | 2012-09-19 | Renascience Co Ltd | INHIBITOR AGENT OF PLASMINOGEN ACTIVATOR INHIBITOR 1 |
| EP2424561A2 (en) | 2009-04-30 | 2012-03-07 | Catherine Blondel | Methods for treating ocular conditions |
| KR20120050442A (ko) | 2009-07-10 | 2012-05-18 | 쓰롬보제닉스 엔.브이. | 플라스미노겐 및 플라스민의 변이체 |
| CN101628113B (zh) | 2009-08-18 | 2012-01-04 | 南京农业大学 | 蚯蚓纤溶酶抗肝纤维化的应用 |
| CN102121023B (zh) | 2010-12-22 | 2012-07-04 | 中山大学 | 突变型人纤溶酶原kringle5及其制备方法及应用 |
| EP2661493B1 (en) | 2011-01-05 | 2016-03-30 | ThromboGenics N.V. | Plasminogen and plasmin variants |
| CN102154253A (zh) | 2011-01-06 | 2011-08-17 | 郑州大学 | 具有抑制血小板凝集功能的微小纤溶酶原突变体及其制备方法和用途 |
| CN102199587B (zh) | 2011-03-24 | 2013-06-19 | 广东药学院 | 人纤溶酶原功能性突变体及其制备方法和应用 |
| US20120058537A1 (en) | 2011-07-27 | 2012-03-08 | Fereidoun Mahboudi | Chimeric truncated and mutant variant of tissue plasminogen activator (t-pa) resistant to plasminogen activator inhibitor-1 |
| JP6000353B2 (ja) | 2011-08-12 | 2016-09-28 | スロンボジェニックス・ナムローゼ・フェンノートシャップＴｈｒｏｍｂｏＧｅｎｉｃｓ ＮＶ | プラスミノーゲンおよびプラスミンの変異体 |
| CN103656630B (zh) | 2012-09-11 | 2015-07-08 | 江苏仁寿药业有限公司 | 一种提纯动物药材中纤溶酶并制备成中药组合物的方法 |
| US9718760B2 (en) | 2012-10-31 | 2017-08-01 | The Regents Of The University Of Michigan | Plasminogen activator inhibitor-1 inhibitors and methods of use thereof |
| WO2014160275A2 (en) | 2013-03-14 | 2014-10-02 | Battell Memorial Institute | Biomarkers for liver fibrosis |
| CN104274449A (zh) | 2013-07-11 | 2015-01-14 | 无锡信达医疗器械有限公司 | 治疗肥胖症的药物组合物 |
| TWI801331B (zh) | 2015-11-03 | 2023-05-11 | 美商波麥堤克生物治療股份有限公司 | 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法 |
| ES2968254T3 (es) | 2015-12-18 | 2024-05-08 | Talengen Int Ltd | Plasminógeno para su uso en la prevención o el tratamiento de la trombosis aguda y la trombosis crónica |
| DK3391902T5 (da) | 2015-12-18 | 2024-09-23 | Talengen Int Ltd | Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati |
| CA3008475C (en) | 2015-12-18 | 2024-06-04 | Talengen International Limited | Method for preventing and treating hepatic tissue injury and related disorders thereof |
| DK3395354T3 (da) | 2015-12-18 | 2024-06-03 | Talengen Int Ltd | Plasminogen til anvendelse i behandling af diabetisk nefropati |
| ES2982294T3 (es) | 2015-12-18 | 2024-10-15 | Talengen Int Ltd | Plasminógeno para su uso en el tratamiento o prevención de lesiones nerviosas por diabetes mellitus |
| EP3251689A1 (en) | 2016-06-02 | 2017-12-06 | IMV Technologies | Use of la1-like peptide isolated from maurus palmatus venom as an activator of sperm motility in mammals |
| WO2018107686A1 (zh) | 2016-12-15 | 2018-06-21 | 深圳瑞健生命科学研究院有限公司 | 一种治疗动脉粥样硬化及其并发症的方法 |
| TWI677348B (zh) | 2016-12-15 | 2019-11-21 | 大陸商深圳瑞健生命科學研究院有限公司 | 一種改善心臟病變的方法 |
| JP7168990B2 (ja) | 2016-12-15 | 2022-11-10 | タレンゲン インターナショナル リミテッド | 肥満症を予防および治療するための方法および薬物 |
| TWI868051B (zh) | 2017-06-23 | 2025-01-01 | 美商波麥堤克生物治療股份有限公司 | 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療 |
| JP6780807B2 (ja) | 2018-07-05 | 2020-11-04 | 三菱電機株式会社 | エレベーターの群管理装置およびエレベーターシステム |
-
2017
- 2017-06-19 TW TW106120460A patent/TWI677348B/zh active
- 2017-06-19 CN CN201780078125.8A patent/CN110114081A/zh active Pending
- 2017-06-19 JP JP2019532072A patent/JP7194440B2/ja active Active
- 2017-06-19 US US16/470,160 patent/US11389515B2/en active Active
- 2017-06-19 EP EP17880564.4A patent/EP3556385A4/en active Pending
- 2017-06-19 CA CA3047175A patent/CA3047175A1/en not_active Abandoned
- 2017-06-19 WO PCT/CN2017/089068 patent/WO2018107707A1/zh not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020502155A5 (https=) | ||
| JP2020511416A5 (https=) | ||
| Kühnast et al. | Innovative pharmaceutical interventions in cardiovascular disease: Focusing on the contribution of non-HDL-C/LDL-C-lowering versus HDL-C-raisingA systematic review and meta-analysis of relevant preclinical studies and clinical trials | |
| Tibaut et al. | Pathophysiology of myocardial infarction and acute management strategies | |
| Garg et al. | Role of niacin in current clinical practice: a systematic review | |
| Head et al. | Coronary artery bypass grafting: part 1—the evolution over the first 50 years | |
| JP2017509624A5 (https=) | ||
| HRP20171950T1 (hr) | Pirimidinoni kao inhibitori faktora xia | |
| JP2020502154A5 (https=) | ||
| Vlachopoulos et al. | Acute effect of sildenafil on inflammatory markers/mediators in patients with vasculogenic erectile dysfunction | |
| FI3562487T3 (fi) | Metalloentsyymi-inhibiittoriyhdisteitä | |
| JP2019206562A5 (https=) | ||
| JP2023090869A5 (https=) | ||
| Kagaya et al. | Low-energy cardiac shockwave therapy to suppress left ventricular remodeling in patients with acute myocardial infarction: a first-in-human study | |
| JP2020528888A5 (https=) | ||
| CN110114081A (zh) | 一种改善心脏病变的方法 | |
| JP2020502134A5 (https=) | ||
| JP2018513846A5 (https=) | ||
| JP2020502135A5 (https=) | ||
| DK1728507T3 (da) | Anvendelse af vitamin K for at omvende forkalkning af blodkar | |
| Yang et al. | Heart failure with preserved ejection fraction and atrial fibrillation: clinical management in the context of recent therapeutic advances in heart failure and electrophysiology | |
| Hassan | HPS2-THRIVE, AIM-HIGH and dal-outcomes: hDL-cholesterol under attack | |
| Cheng | Tezosentan in the management of decompensated heart failure | |
| Güvenç et al. | A novel explanation for the cause of atrial fibrillation seen in atherosclerotic coronary artery disease:“downstream inflammation” hypothesis | |
| Egan et al. | Sympathetic activation and endothelial dysfunction as therapeutic targets in obesity-related hypertension |